Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12557MR)

This product GTTS-WQ12557MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Canlupfam NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12557MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9753MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ15926MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ8739MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ5866MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ4659MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ252MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ11952MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ6439MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW